Carl June, NIBR teams document CAR T resistance

A pair of Nature Medicine studies from CAR T pioneer Carl June and Novartis Institutes for BioMedical Research (NIBR) documented mechanisms that resulted in resistance to Kymriah tisagenlecleucel from Novartis AG (NYSE:NVS; SIX:NOVN) or its precursor CTL019 in

Read the full 387 word article

User Sign In